Renal drug targeting using a vector "alkylglycoside"

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Biochemistry

Background:

• A specific sugar-modified peptide previously showed renal targeting potential in vivo.
• A binding site for this peptide was identified in kidney membrane fractions.
• Understanding structural requirements for renal recognition is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the inhibitory effects of glycosylated derivatives on [3H]Glc-O-C8-AVP binding to kidney membranes.
• To clarify the structural requirements for renal recognition and uptake.
• To evaluate the potential of alkylglycosides as renal targeting vectors.

Main Methods:

• Studied inhibitory effects of various glycosylated derivatives (e.g., Glc-S-C7-Me, Glc-O-C7-Me, Gal-S-C7-Me) on [3H]Glc-O-C8-AVP binding.
• Characterized the binding site of [3H]Glc-S-C7-Me on kidney membranes (Kd, Bmax).
• Evaluated in vivo renal uptake of modified peptides (AVP, tryptamine, 4-nitrobenz-2-oxa-1,3-diazole) conjugated with Glc-S-C8-.

Main Results:

• Octyl beta-D-thioglucoside (Glc-S-C7-Me) significantly inhibited binding, more so than other derivatives.
• [3H]Glc-S-C7-Me showed specific binding to kidney membranes (Kd = 17 nM) and effective in vivo renal uptake.
• Alkylglycoside conjugates of AVP, tryptamine, and 4-nitrobenz-2-oxa-1,3-diazole exhibited clear renal targeting potential.
• Optimal kidney targeting was observed with Glc-S-C11-AVP, suggesting the alkyl chain length is important.

Conclusions:

• The alkylglycoside moiety is critical for effective renal uptake.
• Alkylglycosides are suitable candidate vectors for renal targeting.
• This finding has implications for the development of targeted drug delivery to the kidneys.